SCHEDULE: Apimeds Pharmaceuticals US, Inc. - Schedule 13D Amendment

Inscobee Inc. and Apimeds Inc. file Amendment No. 4 to Schedule 13D, detailing a settlement agreement resolving disputes and granting an irrevocable proxy.

Summary

• Inscobee Inc. and Apimeds Inc. (Reporting Persons) have filed Amendment No. 4 to their Schedule 13D concerning Apimeds Pharmaceuticals US, Inc. (the Issuer).
• This amendment primarily addresses a Settlement Agreement entered into on April 24, 2026, which resolves disputes related to a prior Merger Agreement and related transactions.
• The settlement includes the dismissal of litigation, release of claims, modification of prior agreements, and resolution of alleged events of default against the Reporting Persons.
• A key outcome is the granting of an irrevocable proxy to Dr. Vin Menon and Captain Sandeep Singh Yadav, allowing them to vote the Reporting Persons' shares on specified matters until certain conditions are met or July 30, 2026.
• The Reporting Persons have also been satisfied regarding the existence of approximately 1,000 bitcoin held by or on behalf of the Issuer, verified by independent auditors.
• The Reporting Persons currently intend to act in accordance with the Settlement Documents and have no present plans for extraordinary corporate actions beyond what is stipulated.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it signifies the resolution of significant disputes and the confirmation of digital asset holdings, which addresses prior concerns.

Positives

• Resolution of disputes and litigation through a Settlement Agreement, which includes the dismissal of a lawsuit filed by Erik Emerson.
• Confirmation of approximately 1,000 bitcoin holdings by the Issuer, verified by two independent PCAOB-registered public accounting firms, addressing prior concerns.
• Modification of prior agreements and removal of alleged events of default against the Reporting Persons.
• Establishment of governance, voting, and other arrangements among the parties through the Settlement Documents.

Negatives

• The granting of an irrevocable proxy to external parties (Dr. Vin Menon and Captain Sandeep Singh Yadav) may reduce the Reporting Persons' direct control over voting their shares.
• The settlement implies prior significant disputes and litigation that required resolution.

Risks

• The irrevocable proxy is tied to specific events such as NYSE approval of a Listing Application and completion of Preferred Stock Conversion and Note Approval, creating uncertainty regarding its duration.
• The proxy is also subject to a hard stop date of July 30, 2026, after which its terms may change.
• The Reporting Persons reserve the right to review their investment, indicating potential future changes in their stake or strategy.

Future Outlook

The Reporting Persons intend to act in accordance with the Settlement Documents and currently have no specific plans or proposals that would lead to any of the matters described in Item 4(a)-(j) of Schedule 13D, other than as set forth in the Settlement Documents. They reserve the right to review their investment and take appropriate actions.

Management Comments

• The Reporting Persons have been advised that a PCAOB-registered public accounting firm verified the existence of approximately 1,000 bitcoin on multiple occasions.
• An additional independent PCAOB-registered public accounting firm independently verified such bitcoin holdings.
• Based on the foregoing, the Reporting Persons are satisfied that their prior concerns regarding the existence of such digital assets have been addressed.

Industry Context

StockSavvy.ai notes that this filing reflects a significant development in resolving corporate disputes, a common occurrence in the pharmaceutical and biotech sectors where complex merger and financing agreements are prevalent. The confirmation of digital asset holdings, specifically bitcoin, is also noteworthy as companies increasingly explore or hold such assets.

Corporate Governance

Legal Proceedings

• Dismissal of litigation previously filed by Erik Emerson against the Reporting Persons and/or the Issuer.
• Release of claims related to the Merger Agreement.

Related Party Transactions

• The Settlement Documents address various agreements, arrangements, and understandings among the Reporting Persons and potentially other parties involved in the prior merger and related transactions.

Stakeholder Impact

• Shareholders: The resolution of disputes and confirmation of assets may provide stability. The irrevocable proxy could impact voting power and strategic direction.
• Management: The settlement resolves disputes and may influence future governance arrangements.
• Creditors: Resolution of disputes could impact the company's financial stability and obligations.

Next Steps

• Receipt of NYSE approval of the Listing Application.
• Completion of Preferred Stock Conversion and Note Approval following NYSE approval.
• Monitoring of the Irrevocable Proxy's duration and conditions.
• Reporting Persons may review their investment and take actions as they deem appropriate.

Key Dates

Recommendation

The filing indicates a resolution of significant disputes and confirmation of assets, which is positive. However, the granting of an irrevocable proxy to external parties introduces uncertainty regarding future control and strategic direction. The company's future performance will depend on the successful navigation of post-settlement governance and operational execution. Therefore, a 'hold' recommendation is appropriate pending further clarity on these factors.

Keywords

Schedule 13D, Apimeds Pharmaceuticals, Inscobee Inc., Apimeds Inc., Settlement Agreement, Irrevocable Proxy, Bitcoin Holdings, Corporate Governance, Litigation Resolution, SEC Filing